CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReadCoor, Inc., a company leading true multi-omic spatial sequencing, today unveils its first product line, including multi-omic spatial sequencing assays and the RC2 instrument. The platform is powered by ReadCoors proprietary FISSEQ (Fluorescent in situ Sequencing) technology, which combines the massive multiplexity of next-generation sequencing (NGS) and high-resolution tissue imaging. The fully integrated platform is now available for use by researchers through ReadCoors Select Release Program (SRP), focusing on initial applications in immuno-oncology, neuroscience, and infectious disease, as well as a custom offering. ReadCoor has increased its Series B investment round to $30 million to accelerate commercial efforts.

The new platform simultaneously detects tens to thousands of RNA and DNA sequences, proteins, and therapeutic molecules at nanoscale 3D resolution in every cell within an intact tissue sample. The key products launched today are:

We firmly believe our true multi-omic sequencing technology will have a dramatic impact on medicine and healthcare, and this motivates us to provide researchers products that offer unprecedented and meaningful insights into human biology, said Richard Terry, Chief Executive Officer, Chief Technical Officer, and Founder of ReadCoor. Our Select Release Program serves as the foundation for researchers to develop new therapeutics and treatments to ultimately improve patient care.

Users within the SRP can use ReadCoors initial applications to support their specific research interests. The applications offer the following capabilities:

About ReadCoor, Inc.

ReadCoor is a technology company offering the first true spatial multi-omic platform to the global audience of researchers, clinicians, pharma and diagnostics companies to expand understanding of human biology and facilitate the creation of new therapeutics for patients. The companys RC2 platform simultaneously detects and reads the sequences of tens to thousands of RNA, DNA, proteins and therapeutics and visualizes sub-cellular nanoscale 3D resolution in every cell throughout any tissue section. The platform is based on ReadCoors proprietary Fluorescent in situ Sequencing (FISSEQ) technology, which combines the massive multiplexity of next generation sequencing (NGS) and high-resolution tissue imaging. Learn more at http://www.readcoor.com.

Originally posted here:
ReadCoor, Inc. Unveils True Spatial Sequencing Platform to Drive Groundbreaking Insights into Immuno-oncology, Neuroscience, and Infectious Disease -...